TPH2: A Key Gene Risk Factor and Potential Therapy Target in Depression

Zhang, Xiaoyan; Wang, Yiming

doi:10.1051/e3sconf/202127103070

Cited by 2 publications

(4 citation statements)

References 62 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is located on chromosome 12, the specific location is 12q21.1, and the total number of exons is 13. Some mutations can seriously harm the protein's structure and function as well as its stability and solubility [1,4]. A functional and durable tetramer structure is created when the four TPH2 molecules are connected to their oligomeric domains.…”

Section: Tph2 Genementioning

confidence: 99%

“…Depression is a common neurological disease. Depression severely affects patients' lives and work, and puts a heavy burden on their families and society [1]. The prevalence of depression over the life course is about 15%, and about 15% of depressive patients die by suicide [2,3].…”

Section: Introductionmentioning

confidence: 99%

“…This gene has been found mainly in human beings and mammals. It is located on chromosome 12, the specific location is 12q21.1, and the total number of exons is 13 [1,5]. This gene encodes an enzyme: tryptophan hydroxylase (TPH), and it is mainly found in the presynaptic terminal.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The research progress on related genes affecting depression and their roles in rodent models

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

Depression is a kind of common mental disease, which seriously affects humans' physical and mental health. It is mainly induced by biological, environmental, psychological and genetic factors. The gene that regulates depression is TPH2. The gene encodes the protein in the causation of 5-HT biosynthesis, which has been shown to regulate anxiety, depression and other emotions. A new study recently found that small RNA (miR-RNA) also plays an important role in regulating depression. Among the many animal models, the mouse model was selected for the study of depression. Experiments have been performed in mouse models, and the results showed that serotonin deficiency caused depressionlike behavior in mice that were naturally serotonin deficient, while mice with the TPH2 deletion continued to exhibit depression-like behavior. In addition, over-expression and knockout of miR-323 in the mouse brain also led to increases and decreases in depression behaviors in mouse. In the mouse model, the TPH2 gene and 5-HT can be regulated by gene therapy, but these methods can only be used in the mouse model, and there is still no direct treatment for depression by CRISPR technology. We hope to be able to apply these methods to the treatment of human depression in the future.

show abstract

Section: Tph2 Genementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The research progress on related genes affecting depression and their roles in rodent models

2023

Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022)

View full text Add to dashboard Cite

show abstract

“…These studies suggest that gene therapy for depressive disorder is a real possibility. 104 Some clinical trials of gene therapy are mentioned in Table 7. Examples of other applications of nanotechnology:…”

Section: Gene Therapymentioning

confidence: 99%

The Application of Nanotechnology and Nanomaterials in Depression: An Updated Review

Yadav

Rani

Tyagi

et al. 2023

Precision Nanomedicine

View full text Add to dashboard Cite

Depression is the most common stress-related mental illness. It has an impact on millions of individuals globally. Genetic, biochemical, environmental, and psychological elements can all play a role in its development. Medications, psychotherapy, and lifestyle changes are frequently used to treat depression. Antidepressant medications work by altering the levels of certain chem-icals in the brain. At the same time, psychotherapy aims to help individuals better understand and manage their emotions and thoughts, which otherwise may lead to depression. The current treatment strategy for the illness has several drawbacks, such as adverse effects, ineffectiveness, long-term use, stigma, and cost-related issues of the medication used. These negative effects un-derscore the need for more successful and novel methods of treating depression, such as the investigation of medication delivery techniques based on nanotechnology. Increased medication effectiveness, fewer side effects, long-lasting medication effects, a good understanding of the neural underpinnings of depression, and the potential for the creation of personalized medicines are some of the potential benefits of using nanotechnology in depressive disorder treatment. In several scientific domains, nanotechnology has many benefits. Nanoparticles are the fundamen-tal building blocks of nanotechnology in this regard. Nanoparticles hold great promise for use in medical applications, as recently developed nanotechnology has shown. This review focuses on the most popular nanomaterials that are used to treat depression, in addition to how well these nanomaterials are at managing depression based on their physical, chemical, and biological properties. We have also talked about the difficulties that the various nanomaterials face, which limit their uses and prevent the development of effective clinical therapies.

show abstract

TPH2: A Key Gene Risk Factor and Potential Therapy Target in Depression

Cited by 2 publications

References 62 publications

The research progress on related genes affecting depression and their roles in rodent models

The research progress on related genes affecting depression and their roles in rodent models

The Application of Nanotechnology and Nanomaterials in Depression: An Updated Review

Contact Info

Product

Resources

About